FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

[News]

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

More... (http://www.news-medical.net/news/20101021/FDA-approves-Herceptin-with-chemotherapy-for-HER2-positive-metastatic-cancer.aspx)